Serum Cytokine Concentrations in a Patient with Rheumatoid Arthritis on Etanercept Therapy Who Subsequently Developed Pneumocystis Pneumonia: A Case Report | Zendy

Masao Sato | Zendy; Masao Takemura | Zendy; Ryuki Shinohe | Zendy; Katsuji Shimizu | Zendy

Open Access

Serum Cytokine Concentrations in a Patient with Rheumatoid Arthritis on Etanercept Therapy Who Subsequently Developed Pneumocystis Pneumonia: A Case Report

Author(s) -

Masao Sato,

Masao Takemura,

Ryuki Shinohe,

Katsuji Shimizu

Publication year - 2011

Publication title -

case reports in rheumatology

Language(s) - English

Resource type - Journals

eISSN - 2090-6889

pISSN - 2090-6897

DOI - 10.1155/2011/185657

Subject(s) - etanercept , medicine , rheumatoid arthritis , pneumocystis pneumonia , tumor necrosis factor alpha , pneumonia , gastroenterology , cytokine , necrosis , immunology , pneumocystis jirovecii

We report a rheumatoid arthritis patient who was treated with etanercept. Serum levels of tumor-necrosis-factor- (TNF-) alpha , soluble-tumor-necrosis-factor receptor- (sTNFR-) I and -II, interleukin- (IL-) 6, and IL-1 beta were measured by ELISA before and during the course of therapy. While the serum levels of IL-6 and IL-1 beta dropped rapidly following the initiation of therapy, the concentrations of TNF-alpha and sTNFR-II steadily increased to a plateau. Although significant clinical efficacy was observed, etanercept had to be discontinued when after 12 weeks of therapy the patient was found to have pneumocystis pneumonia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research